GRAIL Corp - GRAL Net earnings per share (EPS TTM)

GRAIL Inc (GRAL) - corporate logo

GRAIL, Inc. (GRAL) is creating a cutting-edge environment for early oncology detection by integrating the Galleri test into the general screening system. The narrow specialization in blood testing is offset by the prospect of US government programs. Revenues are based on the sale of innovative diagnostics. The 12-month YoY earnings per share growth rate on the GURU.Markets chart reflects current dynamics, where the indicator value stands at 18.30.

GRAIL Corp (GRAL) - Net earnings per share for the last 12 months from 11/23/2025 to 11/15/2026

grail.com - analytical breakdowns and key metrics (GRAL)

- share price and consensus valuation forecast:
Share Price GRAIL|GRAL - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization GRAIL Bio|GRAL - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share GRAIL|GRAL - Company Net Assets|Market-to-Book Ratio grail.com|GRAL - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Coefficient GRAIL, Inc.|GRAL - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient grail.com|GRAL - Company Debts|Debts to Net Assets GRAIL Corp|GRAL - Company Long-Term Debts|Short-Term Indebtedness GRAIL|Intermediate Coverage Ratio grail.com
- earnings and valuation multiples indicators:
GRAL - Net Profit|Projected Future Earnings GRAIL, Inc.|GRAL - P/E Multiple|Market Cap to Projected Earnings GRAIL Bio|GRAL - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GRAIL|GRAL - Operating profit before deduction of amortization|Earnings per share for the trailing year GRAIL|GRAL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months grail.com|GRAL - Earnings per share growth in current year|Projected earnings per share growth rate for next year GRAIL, Inc.
- sales volume and revenue information:
GRAL - Revenue and Sales Volume|Company Future Sales Volume GRAIL Corp|GRAL - Market Cap to Revenue|Market Cap to Expected Sales Ratio GRAIL Corp|GRAL - Sales Growth YoY (TTM)
Initial company analysis:GRAL (GRAIL)
Original product of GRAIL, Inc.

GRAIL, Inc. operates within an isolated product cycle where stable demand for innovation renders the business a resilient defensive asset. By analyzing the EPS trend over the last 12 months YoY, an investor assesses the rolling annual growth in earnings per share, which eliminates reporting lags and determines the real margin of safety of the company's fundamental value regardless of market volatility.

Competitor analysis for GRAIL, Inc.

CAI - Net earnings per share (EPS TTM)|GH (guardanthealth.com) - Net earnings per share for the last 12 months|Veracyte Diagnostics (VCYT) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Celcuity Inc.|Earnings per share for the last twelve months MYGN|Net earnings per share for the last 12 months CSTL (Castle Bio)|Net earnings per share for the last four quarters Burning Rock|Earnings per share for the last twelve months volition.com VNRX|Net earnings per share for the last four quarters Biodesix Corp (BDSX)|precipiodx.com - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Check-Cap CHEK|mainzbiomed.com (MYNZ) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months OncoCyte Corp (OCX)